ELI LILLY AND COMPANY Deferred Tax Liabilities, Net
ELI LILLY AND COMPANY (LLY) had Deferred Tax Liabilities, Net of $215.60 million as of 2016-12-31, per its 10-K filed 2018-02-20.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net
us-gaap:DeferredTaxLiabilities · last filed 2018-02-20
- 2016-12-31: Deferred Tax Liabilities, Net $215.60M.
- 2014-12-31: Deferred Tax Liabilities, Net $431.90M.
- 2013-12-31: Deferred Tax Liabilities, Net $670.70M; Deferred Tax Liabilities, Net as first filed $3.12B.
- 2012-12-31: Deferred Tax Liabilities, Net $2.87B.
| Period end | Deferred Tax Liabilities, Net | Deferred Tax Liabilities, Net as first filed |
|---|---|---|
| 2016-12-31 | $215.60M 10-K · filed 2018-02-20 | |
| 2014-12-31 | $431.90M 10-K · filed 2016-02-19 | |
| 2013-12-31 | $670.70M 10-K · filed 2015-02-19 | $3.12B 10-K · filed 2014-02-19 |
| 2012-12-31 | $2.87B 10-K · filed 2014-02-19 | |
| 2011-12-31 | $2.87B 10-K · filed 2013-02-21 | $2.93B 10-K · filed 2012-02-24 |
| 2010-12-31 | $2.91B 10-K · filed 2012-02-24 | -$2.91B 10-K · filed 2011-02-22 |
| 2009-12-31 | -$2.50B 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |